RUNX3 Expression is Lost in Glioma and Its Restoration Causes Drastic Suppression of Tumor Invasion and Migration

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2011 Sep 17

PMID 21922326

Citations 24

Authors

Peng-Jin Mei

Jin Bai

Hui Liu

Chen Li

Yong-Ping Wu

Zheng-Quan Yu

Jun-Nian Zheng

Affiliations

Soon will be listed here.

Abstract

Purpose: The aim of this study is to investigate whether the expression of RUNX3 is related to the development of glioma, and the role of RUNX3 in glioma cells growth, invasion and migration.

Methods: We analyzed the protein expression of RUNX3 by immunohistochemistry in 188 glioma tissues, 8 normal brain tissues and 8 tumor adjacent normal brain tissues using tissue microarray technique. We studied whether RUNX3 restoration can suppress glioma cells growth, invasion and migration by performing MTT cell proliferation assay, matrigel cell invasion assay, wound-healing assay and migration assay. We also detected MMP-2 protein expression and enzyme activity by western blot analysis and gelatin zymography.

Results: We found that RUNX3 expression was decreased in benign tumor and malignant tumor compared with tumor adjacent normal brain tissue (P < 0.01 and P < 0.05, respectively). We did not find any correlation between RUNX3 expression and clinicopathological parameters. In addition, we demonstrated that re-expression of RUNX3 in glioma cells resulted in significantly inhibited cell invasion and migration abilities. This reduced cell invasion and migration abilities were due to MMP-2 protein expression and enzyme activity suppression after RUNX3 restoration.

Conclusions: Our data indicated that RUNX3 expression is significantly decreased in human glioma, and targeting of the RUNX3 pathway may constitute a potential treatment modality for glioma.

Citing Articles

Assessment of differentially methylated loci in individuals with end-stage kidney disease attributed to diabetic kidney disease: an exploratory study.

Smyth L, Kilner J, Nair V, Liu H, Brennan E, Kerr K Clin Epigenetics. 2021; 13(1):99.

PMID: 33933144 PMC: 8088646. DOI: 10.1186/s13148-021-01081-x.

Reverse Engineering of Ewing Sarcoma Regulatory Network Uncovers PAX7 and RUNX3 as Master Regulators Associated with Good Prognosis.

Ribeiro-Dantas M, Imparato D, Dalmolin M, de Farias C, Brunetto A, da Cunha Jaeger M Cancers (Basel). 2021; 13(8).

PMID: 33924679 PMC: 8070584. DOI: 10.3390/cancers13081860.

PIWI-interacting RNAs and PIWI proteins in glioma: molecular pathogenesis and role as biomarkers.

Tamtaji O, Behnam M, Pourattar M, Hamblin M, Mahjoubin-Tehran M, Mirzaei H Cell Commun Signal. 2020; 18(1):168.

PMID: 33109195 PMC: 7590611. DOI: 10.1186/s12964-020-00657-z.

lncRNA MT1JP Suppresses Biological Activities of Breast Cancer Cells in vitro and in vivo by Regulating the miRNA-214/RUNX3 Axis.

Ouyang Q, Cui Y, Yang S, Wei W, Zhang M, Zeng J Onco Targets Ther. 2020; 13:5033-5046.

PMID: 32581560 PMC: 7280253. DOI: 10.2147/OTT.S241503.

Oncosuppressive Role of RUNX3 in Human Astrocytomas.

Steponaitis G, Kazlauskas A, Vaitkiene P, Deltuva V, Mikuciunas M, Skiriute D J Oncol. 2019; 2019:1232434.

PMID: 31467531 PMC: 6699290. DOI: 10.1155/2019/1232434.

References

Subramaniam M, Chan J, Yeoh K, Quek T, Ito K, Salto-Tellez M . Molecular pathology of RUNX3 in human carcinogenesis. Biochim Biophys Acta. 2009; 1796(2):315-31. DOI: 10.1016/j.bbcan.2009.07.004. View

Lund A, van Lohuizen M . RUNX: a trilogy of cancer genes. Cancer Cell. 2002; 1(3):213-5. DOI: 10.1016/s1535-6108(02)00049-1. View

Li Q, Ito K, Sakakura C, Fukamachi H, Inoue K, Chi X . Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell. 2002; 109(1):113-24. DOI: 10.1016/s0092-8674(02)00690-6. View

Sato K, Tomizawa Y, Iijima H, Saito R, Ishizuka T, Nakajima T . Epigenetic inactivation of the RUNX3 gene in lung cancer. Oncol Rep. 2005; 15(1):129-35. View

Kim T, Lee H, Hwang K, Lee M, Kim J, Bang Y . Methylation of RUNX3 in various types of human cancers and premalignant stages of gastric carcinoma. Lab Invest. 2004; 84(4):479-84. DOI: 10.1038/labinvest.3700060. View

Wheeler C, Black K, Liu G, Mazer M, Zhang X, Pepkowitz S . Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res. 2008; 68(14):5955-64. DOI: 10.1158/0008-5472.CAN-07-5973. View

Eng C, Herman J, Baylin S . A bird's eye view of global methylation. Nat Genet. 2000; 24(2):101-2. DOI: 10.1038/72730. View

Cha H, Bae S, Lee H, Lee O, Sato H, Seiki M . Anti-invasive activity of ursolic acid correlates with the reduced expression of matrix metalloproteinase-9 (MMP-9) in HT1080 human fibrosarcoma cells. Cancer Res. 1996; 56(10):2281-4. View

Wu Y, Peck K, Chang Y, Pan S, Cheng Y, Lin J . SCUBE3 is an endogenous TGF-β receptor ligand and regulates the epithelial-mesenchymal transition in lung cancer. Oncogene. 2011; 30(34):3682-93. DOI: 10.1038/onc.2011.85. View

10.

Merk B, Owens J, Lopes M, Silva C, Hussaini I . STAT6 expression in glioblastoma promotes invasive growth. BMC Cancer. 2011; 11:184. PMC: 3118945. DOI: 10.1186/1471-2407-11-184. View

11.

Kim W, Kim E, Jeong P, Quan C, Kim J, Li Q . RUNX3 inactivation by point mutations and aberrant DNA methylation in bladder tumors. Cancer Res. 2005; 65(20):9347-54. DOI: 10.1158/0008-5472.CAN-05-1647. View

12.

Bae S, Takahashi E, Zhang Y, Ogawa E, Shigesada K, Namba Y . Cloning, mapping and expression of PEBP2 alpha C, a third gene encoding the mammalian Runt domain. Gene. 1995; 159(2):245-8. DOI: 10.1016/0378-1119(95)00060-j. View

13.

Brooks P, Stromblad S, SANDERS L, von Schalscha T, Aimes R, Stetler-Stevenson W . Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell. 1996; 85(5):683-93. DOI: 10.1016/s0092-8674(00)81235-0. View

14.

Ichimura K, Vogazianou A, Liu L, Pearson D, Backlund L, Plant K . 1p36 is a preferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas. Oncogene. 2007; 27(14):2097-108. PMC: 2650419. DOI: 10.1038/sj.onc.1210848. View

15.

Barcellos-Hoff M, Newcomb E, Zagzag D, Narayana A . Therapeutic targets in malignant glioblastoma microenvironment. Semin Radiat Oncol. 2009; 19(3):163-70. PMC: 3538148. DOI: 10.1016/j.semradonc.2009.02.004. View

16.

Ito K, Lim A, Salto-Tellez M, Motoda L, Osato M, Chuang L . RUNX3 attenuates beta-catenin/T cell factors in intestinal tumorigenesis. Cancer Cell. 2008; 14(3):226-37. DOI: 10.1016/j.ccr.2008.08.004. View

17.

Zhang Z, Chen G, Cheng Y, Martinka M, Li G . Prognostic significance of RUNX3 expression in human melanoma. Cancer. 2011; 117(12):2719-27. DOI: 10.1002/cncr.25838. View

18.

Mueller W, Nutt C, Ehrich M, Riemenschneider M, Deimling A, van den Boom D . Downregulation of RUNX3 and TES by hypermethylation in glioblastoma. Oncogene. 2006; 26(4):583-93. DOI: 10.1038/sj.onc.1209805. View

19.

Siegel R, Ward E, Brawley O, Jemal A . Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011; 61(4):212-36. DOI: 10.3322/caac.20121. View

20.

Roberts A, Anzano M, Wakefield L, Roche N, Stern D, Sporn M . Type beta transforming growth factor: a bifunctional regulator of cellular growth. Proc Natl Acad Sci U S A. 1985; 82(1):119-23. PMC: 396983. DOI: 10.1073/pnas.82.1.119. View